$ADCT

ADC Therapeutics reported a strong quarterly performance in Q4 2025, exceeding analysts' earnings expectations. The company highlighted increased demand for its latest drug, which has driven revenue growth significantly. Despite some concerns about regulatory hurdles, management expressed confidence in their pipeline. Overall, the results were positively received in the market, indicating potential for future growth. Analysts adjusted their price targets upward following the announcement.